Alantra advises Ypsomed on the sale of its German mail-order subsidiary DiaExpert

Nov 2022

Sell-side advisory

Zürich – Alantra, a global investment banking and asset management specialist, is pleased to announce it has advised Ypsomed (‘The Company’) on the sale of DiaExpert, one of the largest specialists and mail-order retailers for the care of people with diabetes in Germany, to Mediq, a portfolio company of Advent International.  

With over 35 years of experience, Ypsomed is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications.  

The Company presents and markets its product portfolios under the umbrella brands mylife™ and Diabetescare directly to patients or via pharmacies and hospitals, as well as YDS Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. 

DiaExpert is one of the largest specialists and mail-order retailers for diabetes supplies in Germany. Specializing in insulin pump therapy and insulin intensified therapy, it supplies its customers with all the aids and over-the-counter products that are important for daily life with diabetes. DiaExpert is a partner to all German health insurers, ensuring quick and safe delivery while offering a wide range of products and brands.  

Mediq is a portfolio company of Advent international, which provides medical products to specialists in hospitals, other care institutions, and directly to patients at home. With more than 2,500 employees, Mediq currently has operations in 13 countries offering a broad range of products and, among others, operates its own diabetes business in Germany under the brand Mediq Direkt. 

Simon Michel, CEO of Ypsomed, has commented on the transaction: “I am convinced that other opportunities are now open to DiaExpert with Mediq. Digitization offers us the opportunity to develop new forms of therapy management. On our consequent path to becoming a provider of integrated healthcare services, we will from now on focus our portfolio even more strongly on the development, manufacture and distribution of our own products.”  

Martin Menzi, Managing Partner at Alantra, has highlighted: “This transaction marks a key step for our client in the execution of its strategy to focus on own products. We are happy to have found a new home for DiaExpert, allowing the company to further expand and serve even more people suffering from diabetes. We will continue to work closely alongside Ypsomed during the next phase until closing of the transaction.”  

Alantra’s Switzerland office, supported by the Frankfurt office, provided M&A advisory to Ypsomed, acting as their exclusive financial advisor.